Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson?s Disease and Launch of Its Engage Parkinson?s Website

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in patients with Parkinson?s disease, and the launch of its Engage Parkinson?s website.

Click to view original post